Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:SCLN

SciClone Pharmaceuticals (SCLN) Stock Price, News & Analysis

SciClone Pharmaceuticals logo

About SciClone Pharmaceuticals Stock (NASDAQ:SCLN)

Advanced Chart

Key Stats

Today's Range
$11.15
$11.15
50-Day Range
N/A
52-Week Range
$8.55
$11.43
Volume
N/A
Average Volume
444,833 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.

Receive SCLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SciClone Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SCLN Stock News Headlines

Cumberland announces NMPA approval of Vibativ injection in China
PWRHF PWR Holdings Limited
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
SciClone Pharmaceuticals (Holdings) Ltd
SciClone Reaches New 52-Week High (SCLN)
SciClone Pharmaceuticals (Holdings) Limited (6600.HK)
See More Headlines

SCLN Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that SciClone Pharmaceuticals investors own include Bristol-Myers Squibb (BMY), (ONCYF) (ONCYF), Gilead Sciences (GILD), Rite Aid (RAD), Skyworks Solutions (SWKS), Imunon (CLSN) and CTI BioPharma (CTIC).

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:SCLN
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:SCLN) was last updated on 5/7/2025 by MarketBeat.com Staff
From Our Partners